Publication date: Oct 01, 2019
Vertex Pharmaceuticals, the Boston drug maker best known for its cystic fibrosis treatments, continues to branch out, cutting a deal with a North Carolina-based biotech firm that is targeting several serious illnesses, including the fatal genetic disorder Huntington’s disease.
The first collaboration that Ribometrix will focus on is Huntington’s disease.
-Targeting RNA is a potentially powerful new approach” for treating diseases, said Mark Bunnage, a senior vice president and site head for Boston research at Vertex.
Vertex is largely known for its groundbreaking but costly treatments for cystic fibrosis, another rare disease.
|disease||MESH||sickle cell disease|